Jubilant Ingrevia News and Updates

Name: Latest research reports of Jubilant Ingrevia Ltd. authored by Monarch Networth Capital Limited and published by - Trendlyne research reports.
Item: Jubilant Ingrevia Ltd.
Rating: 5
Author: Monarch Networth Capital Limited

Keep track of all breaking news on Jubilant Ingrevia from all sources in a single place.

Load latest

Jubilant Ingrevia Ltd.

17 May 2022

695.50

2.14%

Earnings Call for Q4FY22 of Jubilant Ingrevia

Conference Call with Jubilant Ingrevia Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.

Jubilant Ingrevia Ltd.

17 May 2022

695.50

2.14%

to see Rapid results content

Jubilant Ingrevia Ltd.

01 Feb 2022

695.50

2.14%

Earnings Call for Q3FY22 of Jubilant Ingrevia

Conference Call with Jubilant Ingrevia Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.

audio

Jubilant Ingrevia Ltd.

01 Feb 2022

695.50

2.14%

to see Rapid results content

Jubilant Ingrevia Ltd.

17 Jan 2022

695.50

2.14%

Hot Stocks | Here's why you should bet on Jubilant Ingrevia, Varun Beverages in the short term

Moneycontrol

For the week, 18,350 remains the level to watch. Once it is surpassed, there is no major hurdle visible before 18,600

Jubilant Ingrevia Ltd. is trading below its 100 day SMA of 705.7

Jubilant Ingrevia Ltd.

21 Oct 2021

695.50

2.14%

Jubilant Ingrevia - Risk-Reward Favourable - Q2FY22 Update Note

Buy: Jubilant Ingrevia Ltd.

Monarch Networth Capital Limited

Jubilant Ingrevia (Ingrevia') came out with its Q2FY22 results, which showed significant QoQ de-growth in absolute EBITDA and margins on the back Acetyls (LS Chem EBITDA 14% vs 27% QoQ). Large part of sequential decline was on account of Inventory gains in Q1FY22 and reduction in % spreads. As per us, Q2FY22 can be considered as base for absolute EBITDA in acetyls while the margins may continue to decline on the back of higher Acetic acid prices. Spec Chem margins declined on the back of higher input costs, which should be passed on with a lag. Nutrition business showed sustained volume led growth on the back of Vitamin B3, feed and food business. The stock has had a phenomenal run since our IC on March 18th, 2021 (note) at INR 240 per share, since then the stock is up >3.5x in 7 months! Given the run-up in the chemicals space, we believe Ingrevia remains attractively priced, based on relative valuations as it trades at 12x FY23E EV/EBITDA. We revise our FY22/23 estimates based on the...

Jubilant Ingrevia Ltd.'s price crossed above 50Day SMA today

Jubilant Ingrevia Ltd.

19 Oct 2021

695.50

2.14%

Earnings Call for Q2FY22 of Jubilant Ingrevia

Conference Call with Jubilant Ingrevia Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.

audio

Jubilant Ingrevia Ltd.

19 Oct 2021

695.50

2.14%

Jubilant Ingrevia Q2 profit up 43% YoY to Rs 111 cr

Business Today

The company's revenue for the said quarter jumped 56 per cent to Rs 1,223 crore compared to Rs 406 crore in Q2 FY21. EBITDA grew 44 per cent to Rs 202 crore for Q2 FY22 vs Rs 140 crore in Q2 FY21.

Jubilant Ingrevia Ltd. has an average target of 713.00 from 1 broker.

Jubilant Ingrevia Ltd.

19 Oct 2021

695.50

2.14%

to see Rapid results content

Jubilant Ingrevia Ltd.

22 Sep 2021

695.50

2.14%

Jubilant Ingrevia arm divests 10% stake in Safe Foods Corp for $18.2 mn

Business Standard

Jubilant Ingrevia on Wednesday said its subsidiary Jubilant Life Sciences International Pte Ltd has divested its 10 per cent stake in Safe Foods Corporation for a consideration of $18.2 million